|
An antiviral that is used in the prophylactic or symptomatic treatment of influenza A.
It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and
for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not
well understood but probably reflect an increase in synthesis and release of dopamine,
with perhaps some inhibition of dopamine uptake.
|
References:
|
An acute viral infection involving the respiratory tract. It is marked by inflammation of the nasal mucosa, the pharynx,
and conjunctiva, and by headache and severe, often generalized, myalgia.
[
Articles]
|
|
Pharmacologic Action
-
Antiparkinson Agent
((Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.))
-
Antiviral Agent
(Agents used in the prophylaxis or therapy of virus diseases. Some of the ways they
may act include preventing viral replication by inhibiting viral DNA polymerase; binding
to specific cell-surface receptors and inhibiting viral penetration or uncoating;
inhibiting viral protein synthesis; or blocking late stages of virus assembly.)
-
Dopamine Agent
(Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.)
|
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a tremor that is maximal at
rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness
of voluntary movements, and a masklike facial expression. Pathologic features include loss
of melanin containing neurons in the substantia nigra and other pigmented nuclei of the
brainstem. Lewy bodies are present in the substantia nigra and locus coeruleus but may
also be found in a related condition
characterized by dementia in combination with varying degrees of parkinsonism.
[
Articles]
[
Images]
|
|
